

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/940,986	08/29/2001	Thomas V. Ressemann	891,144-010	6847	
34263 7:	590 11/14/2006	•	EXAM	EXAMINER	
O'MELVENY & MYERS LLP 610 NEWPORT CENTER DRIVE			STIGELL, THEODORE J		
17TH FLOOR			ART UNIT	PAPER NUMBER	
NEWPORT BEACH, CA 92660		•	3763		
			DATE MAIL ED: 11/14/200	DATE MAILED: 11/14/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

·		NI -				
	Application No.	Applicant(s)				
	09/940,986	RESSEMANN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Theodore J. Stigell	3763				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONI	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 11 A	ugust 2006.					
2a)⊠ This action is FINAL . 2b)☐ This	This action is FINAL . 2b) This action is non-final.					
,—- · · ·						
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims						
4) ☐ Claim(s) 1-110 is/are pending in the application 4a) Of the above claim(s) 20-110 is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-19 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	awn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	cepted or b) objected to by the drawing(s) be held in abeyance. So tion is required if the drawing(s) is of	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applica prity documents have been receiv nu (PCT Rule 17.2(a)).	tion No ved in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summar Paper No(s)/Mail I 5) Notice of Informal 6) Other:	Date				

Application/Control Number: 09/940,986

Art Unit: 3763

DETAILED ACTION

Response to Amendment

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-19 rejected under 35 U.S.C. 102(e) as being anticipated by Kokish et al. (6,485,500). Kokish discloses a method of treatment of a blood vessel comprising advancing an evacuation sheath assembly (50) into the blood vessel, stopping normal antegrade blood flow in the blood vessel proximate the stenosis, advancing a therapeutic catheter (44) into the blood vessel, treating the stenosis with the therapeutic catheter, advancing an infusion catheter (34) to a location distal to the stenosis, infusing the blood vessel with a fluid supplied by the infusion catheter, and inducing retrograde flow within the blood vessel to carry the infused fluid and embolic material dislodged during treating into the evacuation sheath assembly.

In regards to claims 2-4, Kokish discloses a method that includes all of the limitations as recited in claim 1 wherein advancing the infusion catheter includes advancing the infusion catheter through a distal end of the evacuation sheath assembly, wherein stopping blood flow includes creating a first seal between the evacuation

sheath and the blood vessel and creating a second seal between a guide catheter and a proximal portion of the evacuation sheath assembly.

In regards to claims 5-9, Kokish discloses a method that includes all of the limitations as recited in claim 1 wherein the retrograde flow includes applying a vacuum through the evacuation sheath, treating the stenosis includes advancing an angioplasty balloon (44), wherein treating the stenosis includes advancing a stent to the stenosis, and wherein inducing retrograde flow involves venting pressure as is well-known in the art.

In regards to claims 10-17, Kokish discloses a method that includes all of the limitations as recited in claim 1 wherein the blood vessel can be a coronary artery or saphenous vein graft, wherein the step of stopping normal antegrade blood flow is performed prior to advancing the device a stenosis, wherein infusing the blood vessel in done through infusion port (42), and wherein saline, blood, or radiopaque dye can be infuse into the blood vessel.

In regards to claim 18-19, Kokish discloses a method that includes all of the limitations as recited in claim 1 wherein the evacuation sheath is advanced through guide catheter and further applying a vacuum to the guide catheter and further comprising inducing retrograde flow prior to advancing the infusion catheter to move debris proximal to the treated stenosis.

Response to Arguments

Applicant's arguments with respect to claims 1-19 have been considered but are moot in view of the new ground(s) of rejection.

Art Unit: 3763

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Theodore J. Stigell whose telephone number is 571-272-8759. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nicholas Lucchesi can be reached on 571-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/940,986 Page 5

Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Theodore J. Stidell

NUCLIOLAS D. LUCCHESI

SURE FIRM ON ON ON THE ARCH